Inactivation of pathogens in platelet concentrates after photochemical treatment with amotosalen and UVA light
| Pathogen . | Log-reduction in organisms . | 
|---|---|
| Enveloped viruses | |
| HIV (cell-free) | > 6.2 | 
| HIV (cell-associated) | > 6.1 | 
| CMV | > 5.9 | 
| Hepatitis B virus | > 5.5 | 
| Hepatitis C virus | > 4.5 | 
| Duck hepatitis B virus | > 6.2 | 
| Bovine viral diarrhea virus | > 6.0 | 
| Human T-cell leukemia virus type I/II | 4.7/5.1 | 
| West Nile virus | > 6.0 | 
| Nonenveloped viruses | |
| Blue tongue | 6.1-6.4 | 
| Parvovirus B19* | 4.0-4.9 | 
| Gram-negative bacteria | |
| Escherhia coli | > 6.4 | 
| Serratia marcescens | > 6.7 | 
| Klebsiella pneumoniae | > 5.6 | 
| Pseudomonas aeruginosa | 4.5 | 
| Salmonella choleraesuis | > 6.2 | 
| Yersinia enterocolitica | > 5.9 | 
| Enterobacter cloacae | 5.9 | 
| Gram-positive bacteria | |
| Staphylococcus aureus | 6.6 | 
| Staphylococcus epidermidis | > 6.6 | 
| Streptococcus pyogenes | > 6.8 | 
| Listeria monocytogenes | > 6.3 | 
| Corynebacterium minutissimum | > 6.3 | 
| Bacillus cereus | > 6.0 | 
| Gram-positive anaerobic bacteria | |
| Lactobacillus species | > 6.9 | 
| Propionibacterium acnes | > 6.7 | 
| Clostridium perfringens | > 7.0 | 
| Bifidobacterium adolescentis | > 6.5 | 
| Protozoa | |
| Trypanosoma cruzi | > 5.3 | 
| Plasmodium falciparum | > 7.0 | 
| Leishmania mexicana | > 5.2 | 
| Pathogen . | Log-reduction in organisms . | 
|---|---|
| Enveloped viruses | |
| HIV (cell-free) | > 6.2 | 
| HIV (cell-associated) | > 6.1 | 
| CMV | > 5.9 | 
| Hepatitis B virus | > 5.5 | 
| Hepatitis C virus | > 4.5 | 
| Duck hepatitis B virus | > 6.2 | 
| Bovine viral diarrhea virus | > 6.0 | 
| Human T-cell leukemia virus type I/II | 4.7/5.1 | 
| West Nile virus | > 6.0 | 
| Nonenveloped viruses | |
| Blue tongue | 6.1-6.4 | 
| Parvovirus B19* | 4.0-4.9 | 
| Gram-negative bacteria | |
| Escherhia coli | > 6.4 | 
| Serratia marcescens | > 6.7 | 
| Klebsiella pneumoniae | > 5.6 | 
| Pseudomonas aeruginosa | 4.5 | 
| Salmonella choleraesuis | > 6.2 | 
| Yersinia enterocolitica | > 5.9 | 
| Enterobacter cloacae | 5.9 | 
| Gram-positive bacteria | |
| Staphylococcus aureus | 6.6 | 
| Staphylococcus epidermidis | > 6.6 | 
| Streptococcus pyogenes | > 6.8 | 
| Listeria monocytogenes | > 6.3 | 
| Corynebacterium minutissimum | > 6.3 | 
| Bacillus cereus | > 6.0 | 
| Gram-positive anaerobic bacteria | |
| Lactobacillus species | > 6.9 | 
| Propionibacterium acnes | > 6.7 | 
| Clostridium perfringens | > 7.0 | 
| Bifidobacterium adolescentis | > 6.5 | 
| Protozoa | |
| Trypanosoma cruzi | > 5.3 | 
| Plasmodium falciparum | > 7.0 | 
| Leishmania mexicana | > 5.2 | 
Data are summarized from Lin,14 Lin et al,15,16,18 Van Voorhis et al,19,20 Dupuis et al,21 Savoor et al,22 and Sawyer et al.23
Preliminary data; inactivation was performed in 35% B19-infected plasma and 65% PAS III (platelet additive solution III) in the absence of platelets. Studies included a 15- or 30-minute rest between addition of amotosalen and UVA treatment